Abstract
Clinical evidence suggests that melanocortin therapy by using adrenocorticotropin (ACTH) is effective in inducing remission of proteinuria in patients with idiopathic membranous nephropathy (MN) and even in those resistant to steroids or other immunosuppressants. Likewise, in passive Heymann's nephritis (PHN), a rat model of MN, ACTH and other non-steroidogenic melanocortins are able to ameliorate glomerular injury and proteinuria. However, the type of melanocortin receptor (MCR) mediating this beneficial effect as well as the underlying mechanism remains controversial.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
